France’s biotech ecosystem: science, capital and scale

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.

Host

⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Ksenija Pavletic, Partner and Chief Commercial Officer, Jeito Capital

Thierry Laugel, Managing Partner, Kurma Partners

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Poddgruvan

France’s biotech ecosystem: science, capital and scale

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

The Golden Triangle and the gaps: Rethinking UK biotech

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

From fragile skin to living medicine: Lessons from RDEB

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Portugal, Spain and the new biotech frontier

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Rethinking hair loss treatment

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck